Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: A Cancer and Leukemia Group B study

Lung Cancer

Volumn 21, Issue 3, 1998, Pages 203-211

  Graziano, Stephen L ^a   Kern, Jeffrey A ^b   Herndon, James E ^c   Tatum, Arthur ^a   Brisson, Marie L ^d   Memoli, Vincent ^e   Sugarbaker, David ^f   Skarin, Arthur T ^g   Kreisman, Harvey ^d   Green, Mark R ^h  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Leukemia Group B; Molecular markers; Neuroendocrine; Tyrosine kinase activity

Indexed keywords

BIOCHEMICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CD57 ANTIGEN; CHROMOGRANIN A; CISPLATIN; ETOPOSIDE; NEURON SPECIFIC ENOLASE; ONCOPROTEIN; SYNAPTOPHYSIN;

ARTICLE; CANCER STAGING; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDIASTINOSCOPY; ONCOGENE C ERB; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL TIME;

CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0032170488     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00063-4     Document Type: Article

References (54)

1. Addis B, Hamid Q, Ibrahim NBN, Fahey M, Bloom SR, Polak JM Immunohistochemical markers of small cell carcinoma and related neuroendocrine tumours of the lung. J Pathol. 153:1987;137-150.
2. Bargmann CI, Hung MC, Weinberg RA The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 319:1986;226-230.
3. Bergh J, Esscher T, Steinholtz L, Nilsson K, Pahlman S Immunocytochemical demonstration of neuron-specific enolase (NSE) in human lung cancers. Am J Clin Pathol. 84:1985;1-7.
4. Bunn PA, Linnoila I, Minna JD, Carney D, Gazdar AF Small cell lung cancer endocrine cells of the fetal bronchus and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells. Blood. 65:1985;764-768.
5. Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, Fernandez-Vasalo G, Abad A, Barnadas A Neuroendocdrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer. 10:1993;209-219.
6. Carney DN, De Leij L Lung cancer biology. Semin Oncol. 15:1988;199-214.
7. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF, Green MR A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med. 323:1990;940-945.
8. Drabnoff G, Bigner DD A word of caution in the use of neuron-specific enolase expression in tumor diagnosis. Arch Pathol Lab Med. 108:1984;535.
9. Fleiss JL. Statistical methods for rates and proportions 2nd ed. New York: John Wiley, 1981.
10. Gazdar AF, Helman LJ, Israel MA, Russell K, Linnoila RI, Mulshine J, Schuller H, Park JG Expression of neuroendocrine cell markers l-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 48:1988;4078-4082.
11. Gazdar AF, Kadoyama C, Venzon D, Park JG, Tsai CM, Linnoila RI, Mulshine JL, Ihde D, Giaccone G Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr. 13:1991;191-196.
12. Gazdar AF, Linnoila RI The pathology of lung cancer-changing concepts and newer diagnostic techniques. Semin Oncol. 15:1988;215-225.
13. Gazdar AF, Linnoila RI, Jewett P, Koros AM, Kortright KH. Natural killer (NK) cell associated antigen NKH-1 is a marker for neuroendocrine tumors of the lung. Proc Am Ass Cancer Res (Abstr 1424) 1987;28:359.
14. Ghoneim AHA, Brisson ML, Fuks A, Mobasher AMMT, Kreisman H Monoclonal anti-CEA antibodies in the discrimination between primary pulmonary adenocarcinoma and colon carcinoma metastatic to the lung. Modern Pathol. 3:1990;613-618.
15. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology 5th ed. Philadelphia PA: Lippincott-Raven, 1997;858-911.
16. Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, Gullo JJ, DiFino SM, Scalzo AJ The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small cell lung cancer. J Clin Oncol. 7:1989;1398-1406.
17. Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, Gamble GP, Coleman MJ, Barmada S, O'Lear S The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res. 54:1994;2908-2913.
18. Hollander M, Wolfe DA Nonparametric statistical methods. 1973;John Wiley, New York.
19. Holmes WE, Sliwkowski MX, Akita RA, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis G, Shepard HM, Kuang W-J, Wood WI, Goeddel DV, Vandlen RL Identification of heregulin, a specific activator of p185erbB2. Science. 256:1992;1205-1210.
20. Hsu SM, Raine L, Fanger H Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem. 29:1981;577-580.
21. Ihde DC Chemotherapy combined with chest irradiation for locally advanced non-small cell lung cancer. Ann Int Med. 115:1991;737-739.
22. Kayser K, Schmid W, Ebert W, Wiedenmann B Expression of neuroendocrine markers (neuronspecific enolase, synaptophysin and bombesin) in carcinoma of the lung. Path Res Pract. 183:1988;412-417.
23. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50:1990;5184-5191.
24. Kumar P, Herndon J, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ Patterns of disease failure after trimodality therapy of non-small cell lung carcinoma pathologic stage IIIA (N2): analysis of Cancer and Leukemia Group B Protocol 8935. Cancer. 77:1996;2393-2399.
25. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. Ca-Cancer J Clin 1998;48:6-29.
26. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A Radiotherapy alone versus combined chemotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 83:1991;417-423.
27. Lee I, Gould VE, Moll R, Wiedenmann B, Franke WW Synaptophysin expressed in the bronchopulmonary tract: neuroendocrine cells neuroepithelial bodies and neuroendocrine neoplasms. Differentiation. 34:1987;115-125.
28. Linnoila RI, Piantadosi S, Ruckdeschel JC Impact of neuroendocrine differentiation in non-small cell lung cancer: the LCSG experience. Chest. 106:1994;367S-371S.
29. Lipinski M, Braham K, Caillaud JM, Carlu C, Tursz T HNK-1 antibody detects an antigen expressed on neuroectodermal cells. J Exp Med. 158:1983;1775-1780.
30. Mantel N Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
31. Mulshine J, Ihde D, Linnoila RI, Veach S, Steinberg S, Woods E, Phelps R, Minna J, Gazdar A Preliminary report of a prospective trial of neuroendocrine marker analysis and in vitro drug sensitivity testing in patients with non-small cell lung cancer (Abstr 713). Proc Am Soc Clin Oncol. 6:1987;181.
32. Mulshine JL, Glatstein E, Ruckdeschel JC Treatment of non-small-cell lung cancer. J Clin Oncol. 4:1986;1704-1715.
33. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Med J 1995;311:899-909.
34. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden T Isolation of the neu/HER-2 stimulating ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell. 69:1992;205-216.
35. Reubi JC, Waser B, Sheppard M, Macaulay V Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer. 45:1990;269-274.
36. Richardson GE, Johnson BE The biology of lung cancer. Semin Oncol. 20:1993;105-127.
37. Rosell R, Gomez-Codina JG, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad A A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 330:1994;153-158.
38. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson EN, Hong WK A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 86:1994;673-680.
39. Ruckdeschel JC, Linnoila RI, Mulshine JL, Kim K, Aisner S, Gazdar AF, Jensen SM, Bonomi P The impact of neuroendocrine (NE) and epithelial (EPI) differentiation on response and survival in lung cancer: the ECOG experience (Abstr 849). Proc Am Soc Clin Oncol. 10:1991;248.
40. Said JW, Vimadalal S, Nash G, Shintaku IP, Heusser RCV, Sassoon AF, Lloyd RV Immunoreactive neuron-specific enolase bombesin and chromogranin as markers for neuroendocrine lung tumors. Hum Pathol. 16:1985;236-240.
41. Scagliotti GV, Leonardo E, Cappia S, Masiero P, Micela M, Gubetta L, Pozzi E Epidermal growth factor receptor and neu-oncogene expression in lung cancer (Abstr 1090). Proc Am Soc Clin Oncol. 12:1993;328.
42. Schleusener JT, Tazelaar HD, Jung SH, Cha SS, Cera PJ, Myers JL, Creagan ET, Goldberg RM, Marschke RF Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated non-small cell lung carcinoma. Cancer. 77:1996;1284-1291.
43. Sheppard MN, Corrin B, Bennett MH, Marangos PJ, Bloom SR, Polak JM Immunocytochemical localization of neuron specific enolase in small cell carcinomas and carcinoid tumours of the lung. Histopathol. 8:1984;171-181.
44. Skov BG, Sorensen JB, Hirsch FR, Larsson LI, Hansen HH Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol. 2:1991;355-360.
45. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem. 269:1994;14661-14665.
46. Sorscher SM, Russack V, Graziano S, Cagle M, Feramisco JR, Green MR Immunohistochemical evaluation of E-cadherin and epidermal growth factor receptor in non-small cell lung cancer. Mod Pathol. 8:1995;450-455.
47. Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer. 64:1991;333-338.
48. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer. 27:1991;1372-1375.
49. Walts AE, Said JW, Shintaku IP, Lloyd RV Chromogranin as a marker of neuroendocrine cells in cytologic material-an immunocytochemical study. Am J Clin Pathol. 84:1985;273-277.
50. neu) in human non-small cell carcinomas of the lung. Cancer Res. 50:1990;421-425.
51. Wiedenmann B, Huttner WB Synaptophysin and chromogranins-secretogranins-widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchow Archiv B Cell Pathol. 58:1989;95-121.
52. Wilson BS, Lloyd RV Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol. 115:1984;458-468.
53. Wilson TS, McDowell EM, Marangos PJ, Trump BF Histochemical studies of dense-core granulated tumors of the lung. Arch Pathol Lab Med. 109:1985;613-620.
54. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K Similarity of protein encoded by the c-erbB-2 gene to epidermal growth factor receptor. Nature. 319:1986;230-234.